Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engages in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. The company has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. The company also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
Follow-Up Questions
Aspire Biopharma Holdings Inc의 CEO는 누구입니까?
Mr. Surendra Ajjarapu은 2023부터 회사에 합류한 Aspire Biopharma Holdings Inc의 Executive Chairman of the Board입니다.
ASBP 주식의 가격 성능은 어떻습니까?
ASBP의 현재 가격은 $0.4383이며, 전 거래일에 decreased 0.44% 하였습니다.
Aspire Biopharma Holdings Inc의 주요 사업 주제나 업종은 무엇입니까?
Aspire Biopharma Holdings Inc은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다